Reshma Kewalramani, Vertex CEO
Vertex nabs ViaCyte's rival diabetes stem cell treatment, acquiring the biotech for $320M in cash
Less than a week after the FDA lifted a hold on Vertex’s stem cell therapy for type 1 diabetes, the Boston company is buying out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
